The American Journal of Managed Care

FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...
Oncology Nurse Advisor

FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division.

Novocure is up 19%. FDA approval is giving the biotech stock a lift.

The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...
Medscape

FDA Approves Wearable Device to Treat Pancreatic Cancer

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...
Medical Device Network

Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device

Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer ...
Business Wire

Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
Business Wire

Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma

Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or ...
pharmaphorum

Celgene hopes device + drug can tackle aggressive brain tumours

Celgene aims to boost the effectiveness of its novel drug marizomib for aggressive brain tumour glioblastoma (GBM) by asking patients to wear a special cap. Marketed by Novocure, the Optune device ...
Nasdaq

China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China

SHANGHAI, China and ST. HELIER, Jersey, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: ...
Yahoo Finance

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

SHANGHAI and ST. HELIER, Jersey, May 13, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (ZLAB), an innovative commercial stage biopharmaceutical company, and Novocure (NVCR), a global oncology company with ...

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...

U.S. FDA Approves Novocure's Optune Pax(R) for the Treatment of Locally Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...